🔗 Share this article

An underground economy for unlicensed slimming drugs is being driven by TikTok fitness influencers and sellers on communication apps, according to recent findings.

Experimental Treatment Acquiring Popularity Via Social Media

The experimental drug, which remains in research studies, is being promoted by online personalities for its alleged weight-reducing effects. Followers are urged to contact these accounts privately for supplier links, while also receiving promotional offers.

Thriving Commerce on Messaging Platforms

Separately, a robust market exists on Telegram, where groups with numerous of participants share “before and after” photos, administration instructions and claims of rapid British shipping. Vendors market the substance there before redirecting customers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could assist patients reduce up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.

Healthcare Professionals Express Worries

Nevertheless, doctors and pharmacists have warned that the sale of what is still an unlicensed drug in the UK is a cause for concern and could result in users administering products of unknown origin.

Several experts stated the demand for retatrutide could be linked to the rising price of licensed slimming products such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on TikTok or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be marketed or distributed for human use under the British medical regulations.

Some content creators try to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still violate medicines, marketing, and customer laws, risking penalties, prosecution or imprisonment.

Platform Response and Content Elimination

According to the social media company, the platform has removed problematic content and prohibited related hashtags and search suggestions. The company stated it was committed to maintaining the platform secure and allocating resources in strengthening enforcement strategies.

Digital Trading Activities

Investigations also discovered groups with up to nine thousand participants marketing retatrutide using the platform's built-in discovery tool, which functions like a public directory. Typing “retatrutide” instantly brings up channels with thousands of members, populated with photos of weight loss, positive reviews and step-by-step guides for preparing or injecting at residence.

After moments of joining one community, a seller shared WhatsApp details, where the majority of purchases take place. The seller sent an guidebook and guaranteed shipping within two days. When asked whether the product was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None asked about weight, health issues or past usage.

Product Information and Pricing

Inside these groups, posts show black plastic parcels with postal service labels, stating to include new batches. One message stated: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at home with sterile water, or pre-filled pens usually priced at 160 pounds for 20mg. When questioned how much time a pen should be used, sellers give conflicting responses ranging from a several days to “depends on your body”.

Service Moderation and Safety Actions

A representative for Telegram stated it actively moderated harmful content on its platform including material that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“Individuals are administering materials they cannot confirm. Even if the research behind this drug is valid, these digital products may not include what they advertise,” said a pharmacy expert, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to recent cost increases for authorized slimming drugs such as Mounjaro. “With costs rising, patients are turning to online platforms. But counterfeit treatments are extremely risky. You cannot know what’s inside or whether the environment they were produced in was sterile,” she said.

Her staff has already seen patients harmed by personal administration from unverified suppliers. “We recognize the disappointment, but buying from messaging apps or communication platforms is gambling with your health,” said Wyllie. “These materials could be impure or improperly measured.”

Manufacturer Position

A representative from Eli Lilly said the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they said, noting that any item “falsely representing itself as a Lilly experimental substance not yet approved … may subject patients to potentially serious medical dangers”.